On February 9, 2022 Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, reported that its President and Chief Executive Officer, Rodney Varner, will provide an overview of the Company’s gene therapies for cancer and diabetes to investors at the 2022 BIO CEO and Investor Conference and at the 2022 Diamond Equity Research Conference (Press release, Genprex, FEB 9, 2022, View Source [SID1234607892]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Details:

Event: BIO CEO and Investor Conference

Conference Dates: February 14-17, 2022

Presentation Time: Available on-demand beginning February 11

Presenter: Rodney Varner, President and Chief Executive Officer

Conference Registration: https://bit.ly/3HgHf4E

Event: Diamond Equity Research Conference

Conference Date: February 24, 2022

Presentation Time: 3 p.m. EST

Presenter: Rodney Varner, President and Chief Executive Officer

Conference Registration: https://bit.ly/3IRPVyT

At these events, Mr. Varner will either be available to participate in virtual one-on-one meetings with registered participants or will be available for questions following the Company presentation. If available, a recording of these presentations will be available for replay on Genprex’s website for a period of time.